Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women

Mehmet Yilmazer1,5, Veysel Fenkci1, Semin Fenkci2, Orhan Aktepe3, Murat Sonmezer4 and Gulay Kurtay4

1Department of Obstetrics and Gynecology, 2 Department of Internal Medicine and 3 Department of Microbiology, Afyon Kocatepe University, Faculty of Medicine, Afyon, and 4Department of Obstetrics and Gynecology, Ankara University, Faculty of Medicine, Ankara, Turkey

5To whom correspondence should be addressed at: Istiklal Mah, Lale Sok, Yeni Candan Apt, A Blok, No. 3, Daire 5, 03200 Afyon, Turkey. E-mail: meyilmazer@hotmail.com

BACKGROUND: Recently published data suggest that hormone replacement therapy (HRT) may increase cardiovascular risk during the early months of therapy. Activation of the immune system is known to be involved in several types of cardiovascular disease. In this cross-sectional study, serum C3, C4, IgG and IgM levels were evaluated in healthy post-menopausal women receiving two different short-term HRT regimens, and in untreated women.

METHODS: Serum C3, C4, IgM and IgG levels were assessed in 18 women receiving transdermal 17β-estradiol (50 μg/day) + continuous oral medroxyprogesterone acetate (MPA; 2.5 mg/day), in 56 women taking oral conjugated equine estrogen (CEE; 0.625 mg/day) + continuous MPA, and in 80 control women not receiving HRT. RESULTS: The mean serum C3 level was significantly higher in women using oral CEE + MPA than in women receiving transdermal 17β-estradiol + MPA, and those not on HRT (P = 0.02 and P < 0.001 respectively). Furthermore, women taking oral CEE + MPA had significantly higher mean levels of C4 compared with untreated women (P < 0.01). IgG and IgM levels were similar among women either of the two HRT regimens and between women not on HRT.

CONCLUSIONS: Oral HRT may be involved in the development of cardiovascular disease through inflammatory mechanisms, as suggested by increased serum levels of C3 and C4.

Key words: C3/C4/hormone replacement therapy/immunoglobulin G/immunoglobulin M

Introduction

Hormone replacement therapy (HRT) relieves menopausal symptoms such as hot flashes and vaginal atrophy, and also prevents osteoporosis in post-menopausal women (Yasui et al., 2000). Numerous epidemiological studies have suggested that HRT reduces the risk of cardiovascular disease in post-menopausal women (Grodstein et al., 1997; Barret-Connor and Grady, 1998). In contrast, a pooled analysis of short-term randomized clinical trials indicated adverse effects, with a relative risk of 1.39 for cardiovascular events (Hemminki and McPherson, 1997). The recently published Women’s Health Initiative (WHI) study showed that the proportion of women experiencing coronary heart diseases was increased by 29% for women taking estrogen plus progestin relative to placebo (Rossouw et al., 2002). The mechanism responsible for the increased cardiovascular risk with HRT use is unclear, but it has been hypothesized that this could be mediated in part through an effect on the inflammatory system, which is intensely involved in cardiovascular disease (Ross, 1999).

The complement system and immunoglobulins are the main components of humoral immunity. The activation of complement is known to be involved in a number of forms of cardiovascular disease. The results of some clinical studies have suggested that complement activation exacerbates myocardial defect following ischaemic injury (Gardinali et al., 1995), is involved in the generation of spontaneous atherosclerotic lesions (Seifert and Kazatchkine, 1988), and may indeed be an initiating factor in lesion formation (Torzewski et al., 1996). C3, the third complement component, is a cytokine and is produced by activated macrophages (Zimmer et al., 1982), which are the cells mainly concerned with the development of atherosclerotic plaques (Libby, 1995). Previous studies have indicated that serum C3 is a powerful indicator of the risk of myocardial infarction (Muscarri et al., 1995; 1998; 2000). Furthermore, there is some evidence suggesting that patients with established atherosclerosis have elevated levels of IgA, IgE, IgG and IgM (Ciriotti et al., 1987; Muscarri et al., 1988). Moreover, elevated levels of IgA, IgE
and IgG are predictive of myocardial infarction (Kovanen et al., 1998).

In the present study, serum concentrations of complement (C3, C4), and immunoglobulin (IgM, IgG) were investigated in women treated with two different short-term HRT regimens for menopausal hormone deficiency symptoms, and in untreated women. To the best of the present authors’ knowledge, this is the first study to determine the impact of HRT on serum complement (C3, C4) and immunoglobulin (IgM, IgG) levels.

Materials and methods
A total of 154 healthy post-menopausal patients aged between 41 and 62 years was enrolled in this cross-sectional study between October 2000 and March 2002. All the participating post-menopausal women were normotensive (blood pressure <140/90 mmHg), non-hysterectomized, and had been menopausal for at least 12 months before entering the study. Informed consent was obtained from all women before participating in the study.

Women with a history of cardiovascular, rheumatismal, autoimmune and malignant diseases, with acute or chronic infection, and those with a clinically relevant abnormality in laboratory tests of immune and malignant diseases, with acute or chronic infection, and before participating in the study.

Informed consent was obtained from all women. To the best of the present authors’ knowledge, this is the first study to determine the impact of HRT on serum complement (C3, C4) and immunoglobulin (IgM, IgG) levels.

Results
The general characteristics of the study and control groups are summarized in Table I. The mean age of patients was similar in the transdermal and control groups, and in the oral group and untreated women. However, CEE + MPA users were younger than transdermal 17β-E2 + MPA users (P < 0.05). Women with or without HRT were similar with respect to duration of amenorrhoea and BMI. Mean FSH levels were lower in the oral than transdermal 17β-E2 + MPA users (P < 0.05). Women who had used HRT or any other hormonal therapy within the previous 12 months were excluded from the control group.

Plasma complement (C3, C4), immunoglobulin (IgM, IgG) and hormone status were evaluated in all participants, and results were compared between control and study groups, as well as among women receiving different HRT regimens.

Blood samples were taken after a fasting period of 10 h in the study and control groups. All laboratory parameters were measured as soon as blood samples were taken. Serum C3, C4, IgG, IgM levels were measured using turbidimetry kits (Biosystem, USA) with an automatic analyser (SPACE, Schiapparelli Biosystem, Inc., USA). This analytical method was applied according to the manufacturer’s instructions. Normal ranges (provided by the manufacturers) for C3, C4, IgG and IgM were: 1.0±1.85 g/l, 0.2±0.45 g/l, 8.4±16.6 g/l and 0.5±2.2 g/l respectively. Daily calibrations were carried out for all measurements made during the study.

Table I. General characteristics of patients in the control and study groups

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control group (n = 80)</th>
<th>Transdermal 17β-E2 + MPA (n = 18)</th>
<th>Oral CEE + MPA (n = 56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>49.9 ± 4.9 (41–62)</td>
<td>51.9 ± 5.1 (46–62)</td>
<td>48.6 ± 4.7 (41–61)*</td>
</tr>
<tr>
<td>Duration of amenorrhoea (years)</td>
<td>4.1 ± 4.5 (1–20)</td>
<td>4.8 ± 5.3 (1–18)</td>
<td>3.2 ± 3.6 (1–20)</td>
</tr>
<tr>
<td>Duration of HRT use (months)</td>
<td>None</td>
<td>4.8 ± 2.5 (3–9)</td>
<td>5.8 ± 2.7 (3–9)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.6 ± 3.5 (22.4–32.6)</td>
<td>27.6 ± 3.8 (22.6–31.5)</td>
<td>26.8 ± 2.8 (22.8–33.4)</td>
</tr>
<tr>
<td>FSH (mIU/ml)</td>
<td>64.5 ± 25.6 (31–109)</td>
<td>52.5 ± 20.6 (22–87)</td>
<td>34.7 ± 18.0 (13–90)*</td>
</tr>
<tr>
<td>Estradiol (pg/ml)</td>
<td>19.7 ± 10.8 (0–30)</td>
<td>50.2 ± 24.2 (21–108)*</td>
<td>64.3 ± 33.7 (12–122)*</td>
</tr>
</tbody>
</table>

Values are mean ± SD (range).

*P < 0.05, difference between women receiving CEE + MPA and women receiving 17β-E2 + MPA.

**P < 0.05, versus 17β-E2 + MPA group and control group.

***P < 0.01, versus control group.

****P < 0.001, versus control group.

BMI = body-mass index; CEE = conjugated equine estrogen; HRT = hormone replacement therapy; MPA = medroxyprogesterone acetate; 17β-E2 = 17β-estradiol.
When both study groups were compared with the control group, women receiving transdermal 17\(\beta\)-E\(_2\) + MPA and without HRT had similar serum levels of C3 and C4, whereas women taking oral CEE + MPA had significantly higher mean values of C3 and C4 compared with controls (for C3, \(P < 0.001\); for C4, \(P < 0.01\); Table II). When the impact of HRT on complement levels with respect to the route of administration was compared, serum C3 levels were significantly higher in the oral group than the transdermal group (\(P = 0.02\)). Serum levels of C4 were higher in the CEE + MPA group than in the 17\(\beta\)-E\(_2\) + MPA group, but not significantly so (\(P = 0.229\)) (Table II). No significant change was observed in any of the serum immunoglobulins (IgG or IgM) with HRT use, irrespective of the route of administration. The serum levels of immunoglobulins were also similar among HRT users and non-users (Table II).

Serum C3 and C4 concentrations were positively and strongly correlated (\(r > 0.6, P < 0.0001\) in all groups). Finally, no significant correlation of C3 and C4 with estradiol, FSH, IgG and IgM levels was detected in any of the groups.

### Discussion

The cross-sectional data obtained from the present studies indicated that plasma concentrations of C3 were significantly higher in healthy post-menopausal women using CEE + MPA than in similar women using transdermal 17\(\beta\)-E\(_2\) + MPA and untreated post-menopausal women. In addition, serum levels of C4 were higher in women receiving CEE + MPA than in similar women not on HRT. No difference was detected in IgG and IgM levels between women taking any HRT regimen and women without HRT.

There is increasing evidence that post-menopausal HRT increases cardiovascular risk (Hemminki and McPherson, 1997; Rossovou et al., 2002). In the Heart and Estrogen/progestin Replacement Study (HERS), HRT appeared to increase the risk of new cardiovascular events in the first year, despite favourable effects on lipids (Hulley et al., 1998). Although the association between an increased cardiovascular risk and the administration of HRT has not yet been clarified, it was suggested that this might be mediated in part through an effect on the inflammatory system (Ross, 1999).

C3 is a cytokine and an acute-phase reactant protein produced by activated macrophages (Zimmer et al., 1982), liver and adipose tissue (Alper et al., 1969; Choy et al., 1992). C3 and its fragments are recognized regulators of the humoral immune response and B-cell proliferation (Lenhardt and Melchers, 1988). C3 complement is also heavily involved in the control of lipid and glucose metabolism through its fragment C3a-des-Arg (Baldo et al., 1993). In addition, serum C3 levels are a potent indicator of the risk of myocardial infarction in men (Muscarì et al., 1995) and, together with C4 levels, have been found to be elevated in patients with severe angiographically assessed atherosclerosis who had already been affected by multiple ischaemic events (Muscarì et al., 1988). A significant prevalence of the ‘fast’ allele of C3 has been demonstrated in atherosclerotic patients with respect to controls (Kristensen and Bruun Petersen, 1978). Furthermore, increasing amounts of data indicate that serum C3 and C4 levels strongly correlate with several cardiovascular risk factors such as age, triglycerides, blood glucose and systolic blood pressure (Muscarì et al., 1988; 1995; 1998; 2000). Finally, complement activation is probably involved in the generation of spontaneous atherosclerotic lesions (Rus et al., 1986; Niculescu et al., 1987; Seifert and Kazatchkine, 1988; Seifert et al., 1998). Activated complement has cell-damaging and chemotactic properties (Marder et al., 1985), and therefore might support the development of intimal lesion or monocyte recruitment at the site of atheroma formation (Muscarì et al., 1995).

From this perspective, the following two questions arise. First, might increased cardiovascular risk—as was demonstrated to emerge during the early period of HRT use in the HERS trial (Hulley et al., 1998)—be associated with the complement system? Second, in what way might the use of HRT affect the complement system? Limited data were available from the literature concerning the association of serum complement levels with HRT. However, HRT in the form of unopposed oral estrogen, or combined estrogen and progestin, increases serum C-reactive protein (CRP) concentrations in post-menopausal women (Cushman et al., 1999a;b; Ridker et al., 1999; Van Baal et al., 1999; Walsh et al., 2000; Luyer et al., 2001; Garnero et al., 2002). As a result of oral HRT use, hepatic synthesis of CRP increases (Van Baal et al., 1999; Herrington et al., 2001). Thus, serum levels of C3—which is an acute-phase reactant synthesized by the liver as CRP (Alper et al., 1969)—might also be raised following increased synthesis in liver due to the first-pass effect of oral

### Table II. Immunological variables of patients in control and study groups

<table>
<thead>
<tr>
<th>Immunological variable</th>
<th>Control group ((n = 80))</th>
<th>Transdermal 17(\beta)-E(_2) + MPA ((n = 18))</th>
<th>Oral CEE + MPA ((n = 56))</th>
</tr>
</thead>
<tbody>
<tr>
<td>C3 (g/l)</td>
<td>1.34 ± 0.45 (0.47–2.35)</td>
<td>1.44 ± 0.42 (0.73–2.09)</td>
<td>1.71 ± 0.44 (0.81–2.76)(^b)</td>
</tr>
<tr>
<td>C4 (g/l)</td>
<td>0.31 ± 0.15 (0.11–1.15)</td>
<td>0.34 ± 0.11 (0.15–0.50)</td>
<td>0.42 ± 0.29 (0.15–2.00)(^c)</td>
</tr>
<tr>
<td>IgG (g/l)</td>
<td>11.67 ± 2.69 (5.88–18.70)</td>
<td>11.59 ± 2.75 (6.58–16.70)</td>
<td>12.28 ± 2.76 (7.04–17.70)</td>
</tr>
<tr>
<td>IgM (g/l)</td>
<td>1.07 ± 0.48 (0.27–2.49)</td>
<td>0.91 ± 0.34 (0.50–1.56)</td>
<td>1.12 ± 0.88 (0.25–4.78)</td>
</tr>
</tbody>
</table>

Values are mean ± SD (range).

\(^aP < 0.001\), versus control group.

\(^bP < 0.02\), versus 17\(\beta\)-E\(_2\) + MPA group.

\(^cP < 0.01\), versus control group.

CEE = conjugated equine estrogen; MPA = medroxyprogesterone acetate; 17\(\beta\)-E\(_2\) = 17\(\beta\)-estradiol.
HRT. Accordingly, no significant difference could be found between women receiving transdermal HRT and untreated women with respect to serum levels of C3 and C4. In transdermal HRT, hormones enter the systemic circulation without a hepatic first pass and, for this reason, serum C3 and C4 levels might not be affected.

The association of total immunoglobulins with cardiovascular disease remains the subject of debate. It has been proposed that serum IgA, IgG and IgE may be associated with cardiovascular disease in dyslipidemic men (Kovanen et al., 1998), but others (Muscari et al., 1988; 1995; 1999) have suggested that the increase in IgM and IgG levels might be a consequence of the primary involvement of C3, as there was no independent association of IgM and IgG with atherosclerosis and myocardial infarction. In agreement with previous findings (Bukh et al., 1987), in the present study no significant difference was found in IgG and IgM levels among women receiving oral or transdermal HRT, or in women not taking HRT.

The present study had certain limitations, the first being that the groups included only healthy women with a low risk of cardiovascular disease, and this may have affected the results. Second, the study was non-randomized, non-placebo-controlled and cross-sectional in design. Third, all of the participants enrolled had an intact uterus, and in order to protect the endometrium a combined HRT was used. The sole effect of progestins on the complement system or immunoglobulins is not known, but it may preclude the drawing of definitive conclusions regarding the effects of estrogen alone.

In summary, oral HRT use may cause significant changes in the serum levels of C3 and C4, which in turn may be associated with an increased risk of cardiovascular events during the early stages of treatment, as in the HERS trial. However, these are preliminary findings, and additional information must be derived from large, controlled studies before any clear-cut conclusions may be drawn.

References


Submitted on January 6, 2003; resubmitted on February 27, 2003; accepted on April 2, 2003